<DOC>
	<DOC>NCT01179971</DOC>
	<brief_summary>Purpose: To investigate into the differential effects of polyunsaturated fatty acids as compared to standard control therapy (olive oil) on disease activity and biochemical parameters in patients with rheumatoid arthritis (RA), resp. psoriasis arthritis (PA).</brief_summary>
	<brief_title>n-3 and n-6 Fatty Acids in Rheumatoid Arthritis</brief_title>
	<detailed_description>Methods: Double-blinded, four-armed randomised controlled trial with 3.0 g/d of either n-3 long chain polyunsaturated fatty acids (LC-PUFA) or gamma linolenic acid (GLA), resp. the combination of 1.5 g/d of each, resp. 3.0 g/d of olive oil over 12 weeks. Outcome parameters disease activity score (DAS28), C-reactive protein, concentrations of n-3 LC-PUFA, resp. GLA in plasma lipids (PL), cholesterol esters (CE), and erythrocyte membranes (EM), and serum concentrations of arachidonic acid (AA). Conventional antirheumatic and immunosuppressive therapies could be changed only within defined limits.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Efamol</mesh_term>
	<criteria>Rheumatoid or Psoriasis arthritis Severe diseases of heart, liver, lung airways Noncompliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>n-3 fatty acids</keyword>
	<keyword>n-6 fatty acids</keyword>
	<keyword>anti-inflammatory action</keyword>
	<keyword>clinical trial</keyword>
	<keyword>randomized double-blinded</keyword>
	<keyword>incorporation of fatty acids</keyword>
</DOC>